LANGUAGE
KOREAN
ENGLISH
LOCATION
COMPANY
R&D
R&D Institute
GMP Center
Clinical Development Status
Publications
PRODUCTS
1st Generation
Overview
CARTISTEM
®
PNEUMOSTEM
®
2nd Generation
Overview
SMUP-IA-01
SMUP-IV-01
R&D Inquiries
BUSINESS
CDMO
Quality System
CDMO Service
Quality Control
Global CDMO
CDMO Inquiries
CELLTREE Cord Blood Bank
MOVITA Nutritional Supplements
IR
Stock Information
Disclosure
Financial Information
IR Inquiries
PR
MEDIPOST on Media
Corporate Brochure
CONTACT US
Customer Center
R&D Inquiries
CDMO Inquiries
IR Inquiries
Search Results
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJS…
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with…
2022/05/31
MEDIPOST gears up to enter the global SMUP-IA-01 market based on clinical result…
2022/04/01
MEDIPOST’s treatment for knee osteoarthritis, enters phase 3 clinical trials in…
2022/03/25
MEDIPOST enters into new business and accelerates its clinical trials in the U.S…
2022/03/17
MEDIPOST’s injectable drug for knee osteoarthritis, SMUP-IA-01, enters phase 2 c…
2021/12/24
MEDIPOST receives approval to proceed with phase 2 clinical trial in Korea for i…
2021/10/27
MEDIPOST requests approval for the phase 2 clinical trial in Korea of its next-g…
2021/07/30
MEDIPOST presents the development progress of its next-generation injectable dru…
2021/07/09
MEDIPOST completes the expansion of its GMP facilities for CARTISTEM, a stem cel…
2021/05/17
MEDIPOST starts cord blood-derived immune cell therapy development with the esta…
2021/04/02
Previous
1
2
3
4
5
…
14
Next
Menu